Patient | Age (yrs) | TNM | Stage | Size (cm) | Grade | Cytology | Meth.Gene | Detected |
---|---|---|---|---|---|---|---|---|

1 | 44 | T_{is}N_{0} | 0 | 0.25 | 2 | Malignant | GSTP1,p16 | Y,Y |

2 | 42 | T_{is}N_{0} | 0 | 0.6 | 2 | Normal | RARβ,RASSF1A | N,N |

3 | 50 | T_{is}N_{0} | 0 | 0.9 | 2 | Normal | RARβ | Y |

4 | 46 | T_{is}N_{0} | 0 | 1.1 | 2 | Benign | RASSF1A | Y |

5 | 51 | T_{is}N_{0} | 0 | mf | 2 | Normal | RASSF1A | Y |

6 | 60 | T_{is}N_{0} | 0 | mf | 2 | Normal | p14 | Y |

7 | 47 | T_{is}N_{0} | 0 | mf | 3 | Malignant | GSTP1,p14 | Y,Y |

8 | 75 | T_{1}N_{0} | I | 0.2 | 1 | Normal | RARβ | Y |

9 | 43 | T_{1}N_{0} | I | 0.9 | 2 | Malignant | GSTP1 | Y |

10 | 51 | T_{1}N_{0} | I | 1 | 3 | Normal | RASSF1A | N |

11 | 56 | T_{1}N_{0} | I | 1.7 | 2 | Normal | RARβ | Y |

12 | 60 | T_{1}N_{0} | I | 2.0 | 2 | Normal | RARβ | Y |

13 | 46 | T_{2}N_{0} | IIA | 3 | 3 | Malignant | GSTP1 | N |

14 | 46 | T_{2}N_{1} | IIB | 0.8 | 3 | Malignant | p14 | Y |

15 | 47 | T_{2}N_{1} | IIB | 1.2 | 3 | Malignant | GSTP1,p16 | Y,Y |

16 | 65 | T_{2}N_{1} | IIB | 2.4 | 3 | Malignant | RARβ,p16 | N,N |

17 | 53 | T_{2}N_{1} | IIB | 3.5 | 3 | Malignant | p16 | Y |

18 | 42 | T_{2}N_{1} | IIB | 4 | 3 | Malignant | GSTP1,RASSF1A | Y,Y |

19 | 35 | T_{2}N_{1} | IIB | 4.5 | 3 | Malignant | RARβ,p14 | Y,Y |

20 | 34 | T_{2}N_{1} | IIB | 4.5 | 3 | Malignant | DAP-K | Y |

21 | 43 | T_{2}N_{1} | IIB | mf | 3 | Malignant | p16 | Y |

22 | 31 | T_{3}N_{1} | IIIA | 7 | 2 | Malignant | GSTP1,p14 | Y,Y |